Leerink Partners Starts Evommune Inc (EVMN) at Outperform

Leerink Partners analyst Thomas Smith initiates coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating and a price target of $42.00.

The analyst comments "Overall, we believe EVO756 and EVO301 both offer pipeline-in-a-product potential to address multiple sizable chronic inflammatory diseases. With upcoming potentially value-inflecting readouts, growing strategic interest in novel therapeutic targets, and sufficient capital to reach these key milestones, we believe EVMN is entering a data catalyst-rich 2026 with significant upside potential and the opportunity to be an important player in immuno-dermatology and broader inflammatory disease space."

For an analyst ratings summary and ratings history on Evommune Inc click here. For more ratings news on Evommune Inc click here.

Shares of Evommune Inc closed at $20.71 yesterday.

You May Also Be Interested In

• Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG
• Alabama Power Co. 5.875% Sr. Notes Series 2007b (ALM) Tops Q2 EPS by 62c
• RideNow Group, Inc. (RDNW) Tops Q2 EPS by 4c